Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period-Reference-Cited by-同舟云学术

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

Published:2008-09-15 Issue:9 Volume:59 Page:1270-1278
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Braun Jürgen,Deodhar Atul,Dijkmans Ben,Geusens Piet,Sieper Joachim,Williamson Paul,Xu Weichun,Visvanathan Sudha,Baker Daniel,Goldstein Neil,van der Heijde Désirée,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference30 articles.

1. NSAIDs in ankylosing spondylitis;Miceli-Richard;Clin Exp Rheumatol,2002

2. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNFα therapy and other novel approaches;Braun;Arthritis Res,2002

3. Treatment of ankylosing spondylitis with disease-modifying antirheumatic drugs;Van der Horst-Bruinsma;Clin Exp Rheumatol,2002

4. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis;Braun;Arthritis Rheum,1995

5. Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies!?;Braun;Ann Rheum Dis,2000

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective;PharmacoEconomics - Open;2023-05-20

2. Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis;The Journal of Rheumatology;2022-07-01

3. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06

4. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases;Annals of the Rheumatic Diseases;2022-05-12

5. Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases;Translational Autoimmunity;2022